Hims & Hers Expands Its Technology-Driven Personalized Virtual Care

AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA Stocks Hims & Hers Expands Its Technology-Driven Personalized Virtual Care December 11, 2025 — 10:32 am EST Written by Debanjana Dey for Zacks-> The renowned health and wellness platform, Hims & Hers Health, Inc. HIMS, operates as a deeply technology-driven digital health platform, using software, data and virtual clinical workflows to deliver personalized care at scale. Its model centers on providing consumers with seamless access to treatment across conditions, supported by digital consultations, personalized prescriptions and vertically integrated fulfillment. HIMS continues to enhance the platform’s intelligence and adaptability through investments in diagnostics, automation and expanded clinical capabilities, enabling more proactive and tailored care experiences.Recent launches further strengthen this technology-enabled foundation. The introduction of Labs, a holistic testing experience, brings data-driven insights directly into the platform, allowing customers to monitor biomarkers and receive doctor-developed action plans. Hims & Hers also expanded into new therapeutic areas, including menopause and perimenopause care, delivering personalized hormonal treatments guided by trained providers. In men’s health, the company unveiled a new category with exclusive access to branded oral testosterone, alongside personalized enclomiphene-based treatments and integrated at-home testing workflows. The platform’s reach is also widening geographically and technologically. The acquisition of Livewell marks Hims & Hers’ official entry into Canada, positioning the company to bring personalized digital care to a broader audience and support the launch of its weight-loss program in the region. Additionally, the acquisition of YourBio Health integrates virtually painless blood-sampling technology into the platform, enabling more convenient diagnostics and fueling future proactive health offerings.TDOC & DOCS' Technology-Driven Digital Health PlatformsTeladoc Health, Inc. TDOC operates a technology-driven digital health platform that integrates virtual care, AI and monitoring tools across hospitals, health systems and consumers. Teladoc Health continues to expand its platform’s capabilities, most recently adding an AI-enabled workplace-safety module to its Clarity monitoring solution, enhancing real-time threat detection and intervention workflows. TDOC positions this innovation alongside its broader virtual-care ecosystem, reinforcing Teladoc Health’s strategy of unifying clinical services, intelligent software, and connected devices to improve care delivery.Doximity, Inc. DOCS advances its technology-driven clinician platform through AI-powered workflow, telehealth and clinical-reference tools built to streamline medical practice. Doximity recently reported record utilization of its AI suite, with strong growth in Doximity Scribe and DoxGPT as physicians increasingly integrate these tools into documentation and clinical reference workflows. Doximity deepened its AI capabilities through the acquisition of Pathway, adding a physician-built dataset and advanced clinical-reference models directly into the platform.HIMS’ Price Performance, Valuation and EstimatesShares of Hims & Hers have gained 56.7% year to date, outperforming the industry’s growth of 8.1%.Image Source: Zacks Investment Research HIMS’ forward 12-month P/S of 3.2X is lower than the industry’s average of 4.9X, but is higher than its three-year median of 2.6X. It carries a Value Score of C.Image Source: Zacks Investment ResearchThe Zacks Consensus Estimate for HIMS’ 2025 earnings per share suggests a 77.8% improvement from 2024.Image Source: Zacks Investment ResearchHims & Hers currently carries a Zacks Rank #3 (Hold).You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Free Report: Profiting from the 2nd Wave of AI Explosion The next phase of the AI explosion is poised to create significant wealth for investors, especially those who get in early. It will add literally trillion of dollars to the economy and revolutionize nearly every part of our lives. Investors who bought shares like Nvidia at the right time have had a shot at huge gains. But the rocket ride in the "first wave" of AI stocks may soon come to an end. The sharp upward trajectory of these stocks will begin to level off, leaving exponential growth to a new wave of cutting-edge companies. Zacks' AI Boom 2.0: The Second Wave report reveals 4 under-the-radar companies that may soon be shining stars of AI’s next leap forward.Access AI Boom 2.0 now, absolutely free >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Teladoc Health, Inc. (TDOC) : Free Stock Analysis ReportHims & Hers Health, Inc. (HIMS) : Free Stock Analysis ReportDoximity, Inc. (DOCS) : Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Tags StocksInvesting Zacks Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com. More articles by this source-> Stocks mentioned TDOC HIMS DOCS More Related Articles This data feed is not available at this time. Data is currently not available • Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.